| Name | Title | Contact Details |
|---|
Korman Healthcare is a Chandler, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
eSight empowers the low vision community and advocates to #SeeNewPossibilities for people with macular degeneration, diabetic retinopathy, and 50+ other conditions that cause vision loss. Founded by electrical engineer, Conrad Lewis, who wanted to help his two legally blind sisters see, eSight has since grown to become the leading sight enhancement platform led by an executive team with the vision to do more. After seven years of research and development, the first eSight Eyewear prototype was released in 2013. Since then, the vision-enhancing electronic technology has changed the lives of thousands of people living with visual impairments and legal blindness by allowing them to retain their independence and achieve greater visual acuity at home, school, work, and play. Soon after the release of eSight 3, Time Magazine named eSight in its list of “The 25 Best Inventions in 2017” and Buzzfeed featured the device on its roster of “6 Inventions Changing British People`s Lives In 2017”. Following eSight 3, the team continued to develop its technology and, in 2020, launched its latest model — eSight 4. It was thoughtfully crafted to be wireless and hands-free allowing users to retain their mobility as well as be lightweight and streamlined for all-day comfort. The eSight 4 was later recognized as the “Best Wearable/Healthcare Hardware/Software of 2021” by the Tech Ascension Awards, which honors companies that possess the most innovative technology in their respective industry.
Elixir Medical Corporation, a privately-funded company based in Milpitas, California, develops next-generation platforms to treat coronary and peripheral artery disease that are designed to restore the adaptive remodeling and pulsatile motion capabilities of the blood vessel. The company`s mission is to transform the care of patients with heart and vascular disease through innovation.
Codan US Corporation is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.